BRPI0414688A - tratamento de doença respiratória com anti-receptor de il-2 - Google Patents

tratamento de doença respiratória com anti-receptor de il-2

Info

Publication number
BRPI0414688A
BRPI0414688A BRPI0414688-3A BRPI0414688A BRPI0414688A BR PI0414688 A BRPI0414688 A BR PI0414688A BR PI0414688 A BRPI0414688 A BR PI0414688A BR PI0414688 A BRPI0414688 A BR PI0414688A
Authority
BR
Brazil
Prior art keywords
receptor
respiratory disease
disease treatment
provides
antibody
Prior art date
Application number
BRPI0414688-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Richard S Shames
Original Assignee
Pdl Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pdl Biopharma Inc filed Critical Pdl Biopharma Inc
Publication of BRPI0414688A publication Critical patent/BRPI0414688A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
BRPI0414688-3A 2003-09-23 2004-09-21 tratamento de doença respiratória com anti-receptor de il-2 BRPI0414688A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50588303P 2003-09-23 2003-09-23
US55297404P 2004-03-12 2004-03-12
PCT/US2004/031640 WO2005030252A1 (en) 2003-09-23 2004-09-21 Treatment of respiratory diseases with anti-il-2 receptor antibodies

Publications (1)

Publication Number Publication Date
BRPI0414688A true BRPI0414688A (pt) 2006-11-28

Family

ID=34396276

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414688-3A BRPI0414688A (pt) 2003-09-23 2004-09-21 tratamento de doença respiratória com anti-receptor de il-2

Country Status (8)

Country Link
US (1) US20050089517A1 (enExample)
EP (1) EP1675615A1 (enExample)
JP (1) JP2007506681A (enExample)
AU (1) AU2004275860A1 (enExample)
BR (1) BRPI0414688A (enExample)
CA (1) CA2538737A1 (enExample)
RU (1) RU2006113701A (enExample)
WO (1) WO2005030252A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47972E1 (en) 2003-11-08 2020-05-05 Prothera Biologics, Inc. Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
PT2291654T (pt) 2008-05-28 2018-06-15 Prothera Biologics Inc Preparação e composição de proteínas inibidoras de interalfa do sangue
US20110236381A1 (en) * 2008-12-10 2011-09-29 Stavros Garantziotis Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease
WO2012155039A1 (en) * 2011-05-12 2012-11-15 Temple University-Of The Commonwealth System Of Higher Education Diagnosis and treatment of copd
CA2885604A1 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of ischemia using inter-alpha inhibitor proteins
CN109789193A (zh) 2016-09-13 2019-05-21 普罗瑟拉生物公司 使用间α抑制蛋白治疗肺病的方法
BR122020025384B1 (pt) * 2016-12-13 2022-07-12 Delinia, Inc Proteínas de fusão e dimérica, usos das mesmas e composição farmacêutica
CA3061164A1 (en) 2017-04-25 2018-11-01 Prothera Biologics, Inc. Methods for quantifying inter-alpha inhibitor proteins
EP3902584A4 (en) * 2018-12-29 2022-09-07 Kaleo, Inc. DEVICES AND METHODS FOR DELIVERING SUBSTANCES IN A PRE-FILLED SYRINGE
EP4037673A4 (en) * 2019-10-04 2023-08-16 R.P. Scherer Technologies, LLC ANTI-CD25-MAYTANSINE ANTIBODY CONJUGATES AND METHODS OF USE THEREOF
US12268847B1 (en) 2021-02-10 2025-04-08 Kaleo, Inc. Devices and methods for delivery of substances within a medicament container
CN118370816A (zh) * 2024-03-22 2024-07-23 中日友好医院(中日友好临床医学研究所) Il-2/抗il-2抗体免疫复合物的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473493A (en) * 1981-04-29 1984-09-25 Immunex Corporation Hybridoma antibody which inhibits interleukin 2 activity
US4411993A (en) * 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4845198A (en) * 1984-05-21 1989-07-04 Immunex Corporation Hybridoma antibody which binds IL-2 receptor
US5336489A (en) * 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU8910891A (en) * 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
AP960A (en) * 1995-04-14 2001-04-20 Glaxo Wellcome Inc Metered dose inhaler for fluticasone propionate.
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
JP3973360B2 (ja) * 1998-07-27 2007-09-12 ノバルティス アクチエンゲゼルシャフト 関節リウマチまたは皮膚疾患の処置に使用するためのｃｄ２５結合分子
CZ20032672A3 (cs) * 2001-04-06 2003-12-17 University Of Bristol CD25 vazebná molekula pro použití při prevenci nebo léčení některých nemocí u pacientů rezistentních na léčbu steroidy
BRPI0316282B8 (pt) * 2002-11-15 2021-05-25 Genmab As anticorpo humano isolado monoclonal, composição, imunoconjugado, molécula biespecífica ou multiespecífica, método e conjunto de diagnóstico para detectar a presença de antígeno cd25 ou uma célula que expressa cd25, e, vetor de expressão

Also Published As

Publication number Publication date
JP2007506681A (ja) 2007-03-22
EP1675615A1 (en) 2006-07-05
RU2006113701A (ru) 2007-11-10
CA2538737A1 (en) 2005-04-07
WO2005030252A1 (en) 2005-04-07
US20050089517A1 (en) 2005-04-28
AU2004275860A1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
BRPI0410129A (pt) uso terapêutico de anticorpos anti-cs1
BRPI0418695A (pt) uso terapêutico de anticorpos anti-cs1
BRPI0412890B8 (pt) método de selecionar um anticorpo anti kir2dl1 ou fragmento de anticorpo de ligação de antígeno
HRP20060033B1 (hr) Humana anti-ngf neutralizirajuä†a antitijela kao selektivni inhibitori ngf rute
SG164369A1 (en) Human anti-b7rp1 neutralizing antibodies
NO20051048L (no) Terapeutisk humant anti-IL-1R1 monoklonalt antistoff
FR15C0009I2 (fr) Compositions de gel phospholipide destinees a l'administration medicamenteuse et des methodes de traitement utilisant celles-ci
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
CY1111812T1 (el) Ανθρωπινα εξουδετερωτικα αντι-ifn-γ αντισωματα ως εκλεκτικοι αναστολεις του μονοπατιου της ifn-γ
CY1118377T1 (el) Syk αναστολεις ιμιδαζοπυραζινης
NZ595262A (en) Use of il-23 and il-27 antagonists to treat autoimmune ocular inflammatory disease
KR101155294B1 (ko) 면역특이적으로 ＢＬｙＳ에 결합하는 항체
HUS1500018I1 (hu) A Bruton-féle tirozin-kináz inhibitorai
BRPI0416603A (pt) anticorpo que se liga ao receptor interleucina-4 (il-4) humano
MA31312B1 (fr) Anticorps anti-ige apoptopiques
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
EA200970469A1 (ru) Антитела-агонисты рецептора trkb и их применение
BRPI0414688A (pt) tratamento de doença respiratória com anti-receptor de il-2
ATE513562T1 (de) Nicht-spezifische immunstimulierende mittel
BRPI0514124B8 (pt) anticorpos monoclonais específicos para il-4 humana, seu uso, composição farmacêutica que os comprende e polinucleotídeos
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.